Serum IL-32γ as a biomarker for remission assessment in systemic lupus erythematosus
Serum IL-32γ is significantly associated with overall disease activity and shows promising discriminatory ability for disease states in SLE and could complement existing tools in treat-to-target strategies, offering a simple serologic marker to guide therapy toward the ultimate goal of GC-free remission.